nivolumab,relatlimab
bms
['relativity-047', 'melanoma']
#melanoma orals #asco22 :
relativity-047 update, continued benefit with pfs, os data not mature enough, continued good safety profile! need more follow-up 
Hematology and Medical Oncology fellow at Duke University, Lebanese, husband to the best anesthesiologist, IO fan, trialist and skin cancer specialist to be!